COAGULATION FACTOR II ACTIVITY ASSAY PLASMA
General Information
HLAB/HOL Code: FAC2
UPHSM LIS Test #: 029950
Schedule:
Testing Time: 1-3 Days
Testing Lab: Mayo Labs
UPHSM LIS Test #: 029950
Schedule:
Testing Time: 1-3 Days
Testing Lab: Mayo Labs
Specimen Info
Only 1 specimen type required, unless otherwise specified
Volume: 1.0 mL Plasma
Temperature: Frozen
Tube Type: Platelet Poor Plasma (sodium citrate)
Collection Info:
Specimen Type: Platelet-poor plasma
Patient Preparation: Patient must not be receiving Coumadin or heparin therapy.
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Specimen must be collected prior to factor replacement therapy
2. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
3. Aliquot plasma into a plastic vial, leaving 0.25 mL in the bottom of centrifuged vial.
4. Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or, ideally, < or =-40 degrees C.
Additional Information:
1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.
Temperature: Frozen
Tube Type: Platelet Poor Plasma (sodium citrate)
Collection Info:
Specimen Type: Platelet-poor plasma
Patient Preparation: Patient must not be receiving Coumadin or heparin therapy.
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Specimen must be collected prior to factor replacement therapy
2. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
3. Aliquot plasma into a plastic vial, leaving 0.25 mL in the bottom of centrifuged vial.
4. Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or, ideally, < or =-40 degrees C.
Additional Information:
1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.
Specimen Acceptability
REJECT DUE TO:
Gross hemolysis: Reject
Gross lipemia: Reject
Gross icterus: Reject
Gross hemolysis: Reject
Gross lipemia: Reject
Gross icterus: Reject
Methods
Optical Clot-Based
Clinical Utilities
Diagnosing a congenital deficiency (rare) of coagulation factor II
Evaluating acquired deficiencies associated with liver disease or vitamin K deficiency, oral anticoagulant therapy, and antibody-induced deficiencies (eg, in association with lupus-like anticoagulant)
Determining warfarin treatment stabilization in patients with nonspecific inhibitors (ie, lupus anticoagulant)
Determining degree of anticoagulation with warfarin to correlate with level of protein S
Investigation of prolonged prothrombin time or activated partial thromboplastin time
Evaluating acquired deficiencies associated with liver disease or vitamin K deficiency, oral anticoagulant therapy, and antibody-induced deficiencies (eg, in association with lupus-like anticoagulant)
Determining warfarin treatment stabilization in patients with nonspecific inhibitors (ie, lupus anticoagulant)
Determining degree of anticoagulation with warfarin to correlate with level of protein S
Investigation of prolonged prothrombin time or activated partial thromboplastin time
CPT Codes
85210
* The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding
is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
Reference Range
Adults: 75-145%
Normal, full-term newborn infants or healthy premature infants may have decreased levels (> or =25%) which may remain below adult levels for > or =180 days postnatal.
Normal, full-term newborn infants or healthy premature infants may have decreased levels (> or =25%) which may remain below adult levels for > or =180 days postnatal.
